Lexaria Bioscience Corp. (NASDAQ: LEXX) Working to Address Declining Antihypertensive Intensification and High Prescription Abandonment Rates, with DehydraTECH-CBD
Lexaria is a global innovator in drug delivery platforms developing DehydraTECH-CBD as a potential treatment for hypertensionA 2022 study documented a decline in the percentage of patients receiving appropriate treatment intensification over the last ten yearsThis decline has been attributed to, among other possible reasons, the side effects of antihypertensive drugsAt the same time, only 24% of adults with hypertension have the condition under control,…